Cargando…

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy

INTRODUCTION: The most recently approved antiretroviral, the integrase inhibitor dolutegravir (DTG), is described to be a very potent drug with a unique resistance profile, but a certain degree of cross-resistance to RAL or EVG induced drug resistance, which is mediated mainly by integrase mutations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Carganico, Andreas, Dupke, Stefan, Ehret, Robert, Berg, Thomas, Baumgarten, Axel, Obermeier, Martin, Walter, Hauke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P217
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225390/ https://www.ncbi.nlm.nih.gov/pubmed/25397494 http://dx.doi.org/10.7448/IAS.17.4.19749

Ejemplares similares

Resistance remains a problem in treatment failure
por: Obermeier, Martin, et al.
Publicado: (2014)

Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory
por: Ehret, Robert, et al.
Publicado: (2014)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Acute hepatitis C virus (HCV) infection in the setting of HIV coinfection: a single-centre 10-year follow-up
por: Ingiliz, Patrick, et al.
Publicado: (2014)

The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects
por: Zong, Jian, et al.
Publicado: (2014)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Clinical application of genotypic co-receptor tropism testing from viral RNA and proviral DNA: week 24 analysis of the Berlin maraviroc cohort
por: Obermeier, MJ, et al.
Publicado: (2010)

Patient preferences for characteristics of antiretroviral therapies: results from five European countries
por: Gazzard, Brian, et al.
Publicado: (2014)

Intermittent viraemia and immune reconstitution in patients with more than 10–15 years of antiretroviral therapy: baseline values still matter
por: Erdbeer, Gesa, et al.
Publicado: (2014)

144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort
por: Wolf, Eva, et al.
Publicado: (2014)

Everything fine so far? Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy
por: Erdbeer, Gesa, et al.
Publicado: (2014)

Cost-effectiveness analysis of protease inhibitor monotherapy vs. ongoing triple-therapy in the long-term management of HIV patients
por: Oddershede, Lars, et al.
Publicado: (2014)

Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens
por: Philippe Küpper-Tetzel, Claus, et al.
Publicado: (2014)

Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE)
por: Cheng, Chien-Yu, et al.
Publicado: (2014)

Acceptability and confidence in antiretroviral generics of physicians and HIV-infected patients in France
por: Allavena, Clotilde, et al.
Publicado: (2014)

Hidden costs of HIV treatment in Spain: inefficiency of the antiretroviral drug packaging
por: Llibre-Codina, Josep M, et al.
Publicado: (2014)

Improved therapy-success prediction with GSS estimated from clinical HIV-1 sequences
por: Pironti, Alejandro, et al.
Publicado: (2014)

Determinants of HIV-1 drug resistance in treatment-naïve patients and its clinical implications in an antiretroviral treatment program in Cameroon
por: Zoufaly, Alexander, et al.
Publicado: (2014)

Hypovitaminosis D in HIV-infected patients in Lisbon: a link with antiretroviral treatment
por: Boura, Márcia, et al.
Publicado: (2014)

Patients’ willingness to take separate component antiretroviral therapy regimens for HIV in the Netherlands
por: Engelhard, Esther, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

High frequency of antiviral drug resistance and non-b subtypes in HIV-1 patients failing antiviral therapy in Cuba
por: Kouri, Vivian, et al.
Publicado: (2014)

Treatment modification in HIV-Infected individuals starting antiretroviral therapy between 2011 and 2014
por: Rappold, Michaela, et al.
Publicado: (2014)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

Transmitted antiretroviral drug resistance in treatment naïve HIV-infected persons in London in 2011 to 2013
por: McFaul, Katie, et al.
Publicado: (2014)

Transmitted antiretroviral drug resistance mutations in newly diagnosed HIV-1 positive patients in Turkey
por: Sayan, Murat, et al.
Publicado: (2014)

Durability of first antiretroviral treatment in HIV chronically infected patients: why change and what are the outcomes?
por: Moniz, Patricia, et al.
Publicado: (2014)

Lipohypertrophy and metabolic disorders in HIV patients on antiretroviral therapy: a systematic multidisciplinary clinical approach
por: Sculier, Delphine, et al.
Publicado: (2014)

Impact of etravirine use on hospitalization rates among highly pre-treated failing HIV-1 infected individuals between 2005 and 2011
por: Lacombe, Jean-Marc, et al.
Publicado: (2014)

Attitudes of serodiscordant couples towards antiretroviral-based HIV prevention strategies in Kenya: a qualitative study
por: Fowler, Nikola, et al.
Publicado: (2014)

Clinical and laboratorial impact of antiretroviral therapy in a cohort of Portuguese patients chronically infected with HIV-2
por: Miranda, Ana, et al.
Publicado: (2014)

The suspected unexpected and serious adverse events of antiretroviral drugs used as HIV prophylaxis in HIV uninfected persons
por: Pietraszkiewicz, Ewa, et al.
Publicado: (2014)

Potential drug–drug interactions in HIV-perinatally infected adolescents on antiretroviral therapy in Buenos Aires, Argentina
por: Cordova, Ezequiel, et al.
Publicado: (2014)

The CD4:CD8 ratio is associated with IMT progression in HIV-infected patients on antiretroviral treatment
por: Bernal, Enrique, et al.
Publicado: (2014)

Quality of life of people living with HIV, preliminary results from IANUA (Investigation on Antiretroviral Therapy) study
por: Venturini, Alberto, et al.
Publicado: (2014)

Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels
por: Kelly Pillay, Sameshnee, et al.
Publicado: (2014)

Effectiveness of a team intervention in reducing modifiable cardiovascular disease risk in HIV-infected subjects on antiretroviral therapy
por: Bloch, Mark, et al.
Publicado: (2014)

Prices of second-line antiretroviral treatment for middle-income countries inside versus outside sub-Saharan Africa
por: Simmons, Bryony, et al.
Publicado: (2014)

Outcomes of initial antiretroviral treatment (ART) among recently diagnosed HIV patients in HIV-TR cohort, 2011–2012
por: Korten, Volkan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0va487dvf33m22obb59pgdl93i